21st Austria weekly - Marinomed Andritz 19/04/2023 [pic1]Marinomed: Marinomed Biotech AG achieved istable total revenues of € 11.3 m 2021: 11.6 m. Cash and cash equivalents increased by 41% to 8.2 5.8 m due the drawdown last tranche EIB financing cost-conscious liquidity management. Further investments in Marinomed's future growth path were reflected earnings development according plan. Thus research expenses remained at a high level 6.9 2022 7.5 The operating result -4.9 was slightly below prior-year figure -4.1 m. Andreas Grassauer CEO says: "2022 another successful year for Marinomed. Although